Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Gibco™ Human Oncostatin M (227 aa) Recombinant Protein, PeproTech®

Click to view available options
Quantity:
1 mg
10 μg
100 μg
250 μg
50 μg
500 μg
Description
Recombinant Human Oncostatin M is a 25.7 kDa protein, containing 227 amino acid residues (full length precursor). This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Oncostatin M (OSM) is a growth and differentiation factor that participates in the regulation of neurogenesis, osteogenesis and hematopoiesis. Produced by activated T cells, monocytes and Kaposi's sarcoma cells, OSM can exert both stimulatory and inhibitory effects on cell proliferation. It stimulates the proliferation of fibroblasts, smooth muscle cells and Kaposi's sarcoma cells, but inhibits the growth of some normal and tumor cell lines. It also promotes cytokine release (e.g. IL-6, GM-CSF and G-CSF) from endothelial cells, and enhances the expression of low-density lipoprotein receptors in hepatoma cells. OSM shares several structural and functional characteristics with LIF, IL-6, and CNTF.

Specifications
Specifications
Accession Number | P13725 |
For Use With (Application) | ELISA, Functional Assay, Western Blot |
Formulation | protein with no preservative |
Gene ID (Entrez) | 5008 |
Molecular Weight (g/mol) | 25.7 kDa |
Name | Human Oncostatin M (227 aa) |
Quantity | 100 μg |
Source | E. coli |
Regulatory Status | RUO |
Endotoxin Concentration | <1 EU/ μg |
Show More |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction